DexCom Inc. ($DXCM) Stock Forecast: Up 4.4% Today

What is DexCom Inc.?

Dexcom (DXCM) is a healthcare company specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company has shown strong growth in revenue and customer base, with a positive outlook from market analysts.

Why is DexCom Inc. going up?

DXCM stock is up 4.4% on Jan 22, 2026 15:40

• Despite challenges like a recent Class 1 recall for some G7 receivers, Dexcom announced an impressive Q3 2024 revenue growth of 22% year-over-year, amounting to $1.2 billion. This growth was fueled by expanding its customer base and launching new products such as the Stelo for non-insulin users.
• Analysts have a positive consensus on DXCM, rating it as a "Strong Buy" with an average price target of $85.00, indicating a potential upside of 22.6%. This positive sentiment stems from the company's strong performance in the healthcare industry and its ability to capture the growing market of diabetes patients embracing CGM technology.
• The rise in DXCM's stock price today is attributed to its strong financial performance, favorable analyst ratings, and the overall growth opportunities in the healthcare sector, particularly in patient monitoring.
• Institutional ownership of DXCM remains high at 97.75%, despite Fisher Funds Management LTD selling a portion of its stake, showcasing ongoing confidence in the company's future prospects and market position.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

Dexcom Reports 22% Revenue Growth to $1.2 Billion in 2024 Amidst Challenges

Dexcom reported strong Q3 2024 revenue growth of 22% year-over-year, reaching $1.2 billion, despite a Class 1 recall for some G7 receivers. The company expanded its customer base to nearly 2.9 million and sees significant potential in the 4.5 million diabetes patients yet to adopt CGM technology, especially with the introduction of its new Stelo product for non-insulin users. Wall Street analysts maintain a positive outlook for DXCM, with an average 1-year price target of $84.81.

https://intellectia.ai/news/stock/dexcom-reports-22-revenue-growth-to-12-billion-in-2024-amidst-challenges

Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM)

BTIG analyst Mark Massaro reiterated a Buy rating on BillionToOne, Inc. Class A (BLLN) with a $160.00 price target, noting a Moderate Buy consensus among analysts with a 45.1% upside. J.P. Morgan analyst Robbie Marcus maintained a Hold rating on Dexcom (DXCM), which has an analyst consensus of Strong Buy with a price target of $85.56. Both companies are in the healthcare sector, and their stock performance and analyst ratings are detailed.

https://www.theglobeandmail.com/investing/markets/stocks/DXCM/pressreleases/37147883/analysts-offer-insights-on-healthcare-companies-billiontoone-inc-class-a-blln-and-dexcom-dxcm/

Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV)

Analysts are showing bullish sentiment towards healthcare stocks Dexcom (DXCM) and AbbVie (ABBV). Dexcom received a "Strong Buy" consensus with an average price target of $85.00, implying a 22.6% upside, while AbbVie gathered a "Moderate Buy" consensus with a $255.47 average price target, suggesting an 18.5% upside from current levels.

https://www.theglobeandmail.com/investing/markets/stocks/ABBV-N/pressreleases/37141701/analysts-are-bullish-on-top-healthcare-stocks-dexcom-dxcm-abbvie-abbv/

Patient Monitoring Stocks Q3 Earnings: iRhythm (NASDAQ:IRTC) Best of the Bunch

The article reviews Q3 earnings for patient monitoring stocks, highlighting iRhythm (NASDAQ:IRTC) as the top performer with a significant revenue beat and strong growth. It also examines the performance of Insulet (NASDAQ:PODD), ResMed (NYSE:RMD), Masimo (NASDAQ:MASI), and DexCom (NASDAQ:DXCM), discussing key financial metrics and market reactions. The industry faces both growth opportunities due to aging populations and chronic diseases, and challenges from R&D costs and regulatory hurdles.

https://finviz.com/news/282348/patient-monitoring-stocks-q3-earnings-irhythm-nasdaq-irtc-best-of-the-bunch

Fisher Funds Management LTD Sells 91,159 Shares of DexCom, Inc. $DXCM

Fisher Funds Management LTD reduced its stake in DexCom, Inc. by 7.0%, selling 91,159 shares but still holding 1,217,090 shares valued at approximately $81.9 million. DexCom represents 2.2% of the fund's portfolio and is its 11th largest holding. Institutional ownership for DexCom is high at 97.75%, with significant new positions initiated by other firms and the company recently beating quarterly earnings estimates, maintaining a "Moderate Buy" analyst rating.

https://www.marketbeat.com/instant-alerts/filing-fisher-funds-management-ltd-sells-91159-shares-of-dexcom-inc-dxcm-2026-01-20/

Trending Today

Coterra Energy Inc. ($CTRA) Stock Forecast: Up 5.1% Today

Manhattan Associates, Inc. ($MANH) Stock Forecast: Down 6.6% Today

Workday Inc. ($WDAY) Stock Forecast: Down 9.1% Today

United Rentals Inc. ($URI) Stock Forecast: Down 16.1% Today

Altria Group Inc. ($MO) Stock Forecast: Down 5.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.0% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Down 5.4% Today

Oracle Corporation ($ORCL) Stock Forecast: Down 5.8% Today

Synopsys Inc. ($SNPS) Stock Forecast: Down 6.4% Today

Microsoft Corporation ($MSFT) Stock Forecast: Down 11.9% Today

DexCom Inc. Price History

05.00.2026 - DXCM Stock was up 2.8%

• The bullish movement in DXCM stock today can be attributed to the company's position at an inflection point in the competitive glucose-monitoring market, with positive sentiment from analysts on its future prospects.
• Recent insider transactions, including some purchases at lower prices, suggest continued long-term confidence in DXCM despite short-term valuation concerns, contributing to the positive momentum.
• The company's innovative products and favorable regulatory environment are likely driving investor optimism and contributing to the stock's strong performance in today's trading session.

10.11.2025 - DXCM Stock was up 4.1%

• The rise in DXCM's stock price could be linked to investors potentially seeing recent class action lawsuits and allegations as temporary hurdles that DexCom can navigate.
• Despite legal concerns regarding unauthorized design alterations to its devices and resulting reliability and health issues, investors may have confidence in DexCom's ability to tackle these challenges and uphold its market position.
• Investor faith in DXCM may also be bolstered by positive updates or announcements regarding the company's product pipeline, partnerships, or financial performance, overshadowing the short-term legal uncertainties.
• Overall, today's bullish movement in DXCM's stock suggests that investors are concentrating on the company's long-term growth potential and resilience in the face of legal obstacles, rather than solely dwelling on the ongoing lawsuits and allegations.

11.10.2025 - DXCM Stock was up 5.7%

• The rise in DXCM's stock value may stem from investors perceiving the recent securities fraud class action lawsuits as temporary obstacles that DexCom will likely surmount.
• Despite the legal hurdles, investor confidence in DexCom's capacity to innovate within the healthcare technology industry could be bolstering the stock's performance.
• Growing interest in the stock might also be a result of speculation surrounding potential resolutions or settlements related to the securities law violations, fostering a positive outlook among traders.

12.00.2026 - DXCM Stock was up 5.3%

• DexCom's stock had a notable bullish trend, propelled by robust preliminary Q4 results that surpassed revenue expectations and demonstrated significant growth in both domestic and international markets.
• The introduction of DexCom's G7 15-Day sensor and the FDA approval for Smart Basal technology have been key factors in fostering positive market sentiment, revealing a high demand for the company's advanced products.
• Analysts at Morgan Stanley maintained an Overweight rating for DexCom, pointing to the strong Q4 results and the appointment of a new CEO as favorable catalysts for the company's future growth.
• While there are varied analyst opinions on DexCom's valuation, the general market sentiment remains optimistic, with investors looking forward to the company's sustained revenue growth, enhanced margins, and expansion strategies for 2026.

11.10.2025 - DXCM Stock was up 5.1%

• Today's bullish movement in DXCM's stock may be linked to the favorable market response to its robust Q3 growth and expanded CGM coverage, positioning the company for ongoing adoption despite growing competition.
• Despite facing legal challenges such as securities fraud class action lawsuits and allegations of securities law violations, investors appear to be more focused on the company's growth potential and momentum driven by innovation.
• While some investors have taken a bearish stance in the options market, this sentiment does not seem to have significantly impacted DXCM's stock performance today, as the overall optimistic outlook on the company's future prospects overshadowed these issues.

12.00.2026 - DXCM Stock was up 5.1%

• Dexcom experienced a strong bullish movement recently due to several positive factors:
• The fourth-quarter revenue surpassed expectations, mainly due to the successful launch of the G7 15-Day sensor, showcasing the company's innovation and responsiveness to market needs.
• The appointment of a new President and CEO, Jake Leach, coupled with plans to introduce an AI-enabled Stelo app, reflects a strategic shift towards advanced technology in diabetes management.
• Analysts have expressed optimistic views on Dexcom's performance for 2026, projecting revenue growth and improved margins, which has boosted investor confidence and generated a bullish sentiment.
• Despite concerns raised by some analysts about weaker gross margins and potential pricing pressures, Dexcom's proactive approach to product development and leadership changes has outweighed these worries, leading to an increase in the stock price.

13.10.2025 - DXCM Stock was up 5.1%

• An upcoming lead plaintiff deadline in a securities lawsuit may have initially caused volatility in the stock.
• Despite bearish opinions in the options market, positive news surrounding DXCM's strong growth in Q3 and focus on innovation likely reassured investors and supported the bullish movement.
• Ongoing securities fraud class action lawsuits and legal reminders could have led to short-term fluctuations. However, the overall positive view on DXCM's performance and market position has been more prominent, driving the bullish trend.
• Investors appear to be placing more emphasis on the company's growth potential and competitive standing rather than its legal challenges, leading to an increase in the stock price.

06.00.2026 - DXCM Stock was up 5.1%

• The bullish movement in DXCM stock today can be attributed to the unveiling of a new app feature by a competitor aimed at enhancing mealtime decisions for individuals with diabetes. This innovation in the diabetes management space may have positively influenced investor sentiment towards DexCom.
• The market may also be reacting to the detailed overview of DexCom's stock performance and financial data, showcasing its fundamental strength and role in continuous glucose monitoring systems.
• Additionally, the nuanced view on Dexcom's valuation and long-term growth prospects from top institutional shareholders and recent insider trades might have instilled confidence in investors, contributing to the bullish momentum.

22.00.2026 - DXCM Stock was up 4.4%

• Despite challenges like a recent Class 1 recall for some G7 receivers, Dexcom announced an impressive Q3 2024 revenue growth of 22% year-over-year, amounting to $1.2 billion. This growth was fueled by expanding its customer base and launching new products such as the Stelo for non-insulin users.
• Analysts have a positive consensus on DXCM, rating it as a "Strong Buy" with an average price target of $85.00, indicating a potential upside of 22.6%. This positive sentiment stems from the company's strong performance in the healthcare industry and its ability to capture the growing market of diabetes patients embracing CGM technology.
• The rise in DXCM's stock price today is attributed to its strong financial performance, favorable analyst ratings, and the overall growth opportunities in the healthcare sector, particularly in patient monitoring.
• Institutional ownership of DXCM remains high at 97.75%, despite Fisher Funds Management LTD selling a portion of its stake, showcasing ongoing confidence in the company's future prospects and market position.

07.10.2025 - DXCM Stock was down 5.1%

• The decrease in DXCM stock value might be linked to legal actions taken against the company alleging securities fraud, which has caused uncertainty among investors.
• Despite reporting strong double-digit growth in Q3 earnings and increasing its projected revenue for 2025, the stock price dropped, potentially indicating that the legal issues have overshadowed the positive financial performance.
• Investor sentiment towards DXCM appears pessimistic, possibly driven by worries concerning the lawsuits' impact on the company's image and long-term growth prospects.

31.09.2025 - DXCM Stock was down 15.0%

• Despite surpassing earnings and revenue estimates in Q3, DexCom's stock experienced a bearish movement possibly due to ongoing securities class action lawsuits.
• Investor uncertainty may have increased as investigations into potential breaches of fiduciary duties by certain officers and directors were revealed, further impacting confidence in the company.
• Analysts initially highlighted positive earnings growth potential, but the overshadowing legal issues and declining short interest may have contributed to the bearish market movement today.

31.09.2025 - DXCM Stock was down 14.3%

• Despite strong growth in Q3 and an increase in revenue projections for 2025, DXCM saw a decline in its stock price, signaling a disconnect between its performance and investor expectations.
• An ongoing examination into potential breaches of fiduciary duties by certain company officials could have contributed to investor unease and the stock's bearish performance.
• Legal actions initiated by a law firm on behalf of DXCM investors within a specific timeframe might have added to the negative market sentiment surrounding the company.
• Even surpassing Q3 earnings and revenue forecasts may not have been enough to counterbalance overarching market apprehensions and legal uncertainties, resulting in the decline in the stock's value.